Cord Blood America CEO Interview Details the Value of New 'Afford-A-Cord' Program

Jun 04, 2010, 05:12 ET from Cord Blood America, Inc.

LAS VEGAS, June 4 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com ) (OTC Bulletin Board: CBAI), said today that its co-founder and CEO, Matthew Schissler, reviewed the reasons for and significant details about its new "Afford-A-Cord" program in an interview with analyst Francis Gaskins.

The entire interview is available at:

http://gaskinsco.com/cbai-6-3-10.mp3

The "Afford-A-Cord" program, which is being launched this month, reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service.  

"The program is being offered as an additional payment option to our longstanding traditional payment programs," Mr. Schissler said in the interview.  "We are breaking new ground as we open up this service to an entire new sector of people who want to store their child's stem cells at birth. The number one objection to using our services is the pricing at time of birth.  We believe this new program will solve that issue for many families."

Mr. Schissler, in the interview, which is a detailed presentation on why the Company is offering the program, said it will increase Cord Blood America's total number of assets, increase its customer base and increase the value of each individual contract.  "It brings more valuable assets to our balance sheet," Cord Blood America's CEO said.

"The program, if successful, will put enormous pressure on our smaller competitors, who do not have their own laboratories for storage, to consolidate.  We still have a vociferous appetite for acquisitions," Mr. Schissler said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.



RELATED LINKS

http://www.cordblood-america.com


http://www.corcell.com/